Clinical Trials

121 enrolled

Colorectal Neoplasms

NCT03828799 2026-02-27

FOLFIRINOX-R

Phase 1/2 Completed

13 enrolled 22 charts

Colorectal Neoplasms

NCT03712943 2026-02-09

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

52 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

39 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03377361 2025-12-03

CheckMate 9N9

Phase 1/2 Completed

325 enrolled 31 charts

Colorectal Neoplasms

NCT05839951 2025-11-12

STAR-T

818 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Colorectal Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

123 enrolled 21 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

673 enrolled

Colorectal Neoplasms

NCT06029010 2025-02-26

COLONGER

2,326 enrolled

Colorectal Neoplasms

NCT03564938 2024-12-03

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Phase 4 Completed

100 enrolled

Colorectal Neoplasms

NCT02175095 2024-10-04

[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

Phase NA Completed

68 enrolled 15 charts

Colorectal Neoplasms

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

GastrointestinalGenitourinary

6 enrolled 11 charts

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT02316340 2024-01-05

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

42 enrolled 8 charts

Colorectal Neoplasms

NCT02195011 2023-12-05

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

26 enrolled 12 charts

Colorectal Neoplasms

NCT03215264 2023-11-09

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

20 enrolled 9 charts

Colorectal Neoplasms

NCT02106858 2023-07-24

StivargaPMS

316 enrolled

GastrointestinalSarcoma

Neoplasm Metastasis, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT04126733 2023-07-18

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

70 enrolled 15 charts

Colorectal Neoplasms

NCT03829852 2021-07-23

Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients

716 enrolled

Colorectal Neoplasms

NCT01298570 2021-01-06

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

181 enrolled 18 charts

Colorectal Neoplasms

NCT03081494 2020-12-11

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

10 enrolled

Colorectal Neoplasms

NCT02835924 2020-03-10

RE-ARRANGE

299 enrolled

Colorectal Neoplasms

NCT02788279 2019-12-11

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

363 enrolled 19 charts

Colorectal Neoplasms

NCT02651415 2019-09-12

PARICCA

12 enrolled 13 charts

Colorectal Neoplasms

NCT01853319 2019-04-22

REGARD

100 enrolled

Colorectal Neoplasms

NCT02116894 2019-03-14

REGAL-1

11 enrolled

Colorectal Neoplasms

NCT02699073 2019-02-28

TEXCAN

55 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT01996969 2019-02-22

Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer

Phase NA Completed

117 enrolled

Colorectal Neoplasms

NCT02465502 2018-11-07

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

59 enrolled

Colorectal Neoplasms

NCT03698253 2018-10-05

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Phase NA Completed

41 enrolled

Colorectal Neoplasms

NCT02347852 2018-09-10

REGO-ACT

25 enrolled

Colorectal Neoplasms

NCT01843400 2018-08-02

Regorafenib Post-marketing Surveillance

1,301 enrolled

Colorectal Neoplasms

NCT02800330 2018-08-02

REGORA

Phase 4 Completed

31 enrolled

GastrointestinalSarcoma

Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03386825 2018-05-15

COLONG

76 enrolled

Colorectal Neoplasms

NCT02656524 2018-02-12

Stivarga Real Life Evidence in Hungary

400 enrolled

Colorectal Neoplasms

NCT02042144 2018-01-16

Correlate

1,034 enrolled

Neoplasms, Colorectal Neoplasms

NCT01875380 2017-08-01

REFRAME

46 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT01584830 2016-02-08

CONCUR

204 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT01103323 2015-06-24

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

760 enrolled 14 charts

Colorectal Neoplasms

NCT00934882 2014-06-02

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

45 enrolled